...
首页> 外文期刊>Mediators of inflammation >Shexiang Baoxin Pill Alleviates the Atherosclerotic Lesions in Mice via Improving Inflammation Response and Inhibiting Lipid Accumulation in the Arterial Wall
【24h】

Shexiang Baoxin Pill Alleviates the Atherosclerotic Lesions in Mice via Improving Inflammation Response and Inhibiting Lipid Accumulation in the Arterial Wall

机译:Shechiang Baoxin丸通过改善炎症反应并抑制动脉壁的脂质积累来减轻小鼠中的动脉粥样硬化病变

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Epidemiological studies have demonstrated that cardiovascular diseases (CVDs) are the leading cause of death in the world. Atherosclerosis, a kind of chronic vascular disorder related to multiple pathogenic processes, has been reported to be an underlying cause of CVDs. Shexiang Baoxin Pill (SBP) is a traditional Chinese medicine formulation and has been broadly used for the treatment of CVDs in East Asia. However, whether SBP affects the development of atherosclerosis is poorly understood. The aim of this study was to investigate the antiatherosclerotic roles and relevant mechanisms of SBP in apolipoprotein E knockout mice. Our results showed that SBP treatment markedly decreased the size of atherosclerotic plaques of the entire aorta and the aortic sinus. Biochemical analyses indicated that SBP gavage improved oxidative stress in vivo, as seen by the level elevation of SOD, CAT, and GSH and the level reduction of MDA, H2O2, and MPO. Moreover, the concentration of MCP-1, IFN-γ, and IL-17A was reduced, and the content of IL-10 and TGF-β1 was increased in the serum from SBP-treated mice. We discovered that the expression levels of inflammatory factors including VCAM-1, ICAM-1, IL-6, and IL-2 in the vascular wall of the SBP group were also decreased in comparison with those of the normal saline group. Moreover, we found that SBP alleviated the activation of inflammation-related pathways in the aorta tissue, as seen by the level elevation of Mfn2 and reduced phosphorylation of p38, JNK, and NF-κB. Furthermore, western blot showed that SBP administration reduced the level of SR-A and LOX-1 and elevated the content of LXRα, ABCA1, and ABCG1 in the arterial wall, indicating that SBP was capable of alleviating lipid influx and facilitating lipid efflux. In conclusion, our data suggested that SBP exerted antiatherosclerotic effects via improving inflammation response and inhibiting lipid accumulation.
机译:流行病学研究表明,心血管疾病(CVDS)是世界上死亡的主要原因。据报道,动脉粥样硬化,一种与多种致病过程相关的慢性血管障碍是CVDS的潜在原因。 Shechiang Baoxin Pill(SBP)是一种中药制剂,广泛用于东亚CVDS的治疗。但是,SBP是否会影响动脉粥样硬化的发展是不知情的。本研究的目的是探讨载脂蛋白E敲除小鼠中SBP的抗炎症和相关机制。我们的研究结果表明,SBP治疗明显降低了整个主动脉和主动脉窦的动脉粥样硬化斑块的大小。生物化学分析表明,SBP饲料改善了体内氧化应激,如SOD,CAT和GSH的水平升高以及MDA,H2O2和MPO的水平降低所见。此外,降低了MCP-1,IFN-γ和IL-17a的浓度,并且在SBP处理的小鼠中血清中的IL-10和TGF-β1的含量增加。我们发现,与生理盐水组的那些,SBP组血管壁中的炎症因子的表达水平也在SBP组的血管壁中的血管壁中的表达水平也降低。此外,我们发现SBP缓解了主动脉组织中炎症相关途径的激活,如MFN2的水平升高所见,并降低P38,JNK和NF-κB的磷酸化。此外,Western印迹表明,SBP给药降低了Sr-A和LOX-1的水平,并升高了动脉壁中的LXRα,ABCA1和ABCG1的含量,表明SBP能够减轻脂质流入并促进脂质流出。总之,我们的数据表明,SBP通过改善炎症反应和抑制脂质积累来施加抗炎症效应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号